Alexandros Makriyannis is a professor in the Department of Medicinal Chemistry at Northeastern University, where his research group has synthesized many new compounds with cannabinoid activity. Some of those are:
| Name | Class | data-sort-type="number" | Ki / nM at CB1 | data-sort-type="number" | Ki / nM at CB2 | data-sort-type="number" | Selectivity | data-sort-type="number" | CLogP | Structure | Description |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.43 | 6.47 | An analgesic CB1 agonist derived from Δ8-THC substituted with a side chain on the 3-position, roughly 100 times as potent as THC. | |||||||||
| Pyrazole derivative | 7.5 | 7.08 | An inverse agonist at the CB1 cannabinoid receptor that is structurally related to SR141716A (rimonabant), but has a higher binding affinity.[1] | ||||||||
| A Schedule I substance in Alabama.[2] | |||||||||||
| N-(morpholin-4-yl)-1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-1H-pyrazole-3-carboxamide | |||||||||||
| 17.9 | 868 | 5.55 | A synthetically created stable chiral analog of anandamide, it acts on both cannabinoid receptors.[3] | ||||||||
| Palmitylsulfonyl fluoride[4] | |||||||||||
| Stearylsulfonyl fluoride | |||||||||||
| 7.02 | An active metabolite of paracetamol (acetaminophen) and a likely inhibitor of fatty acid amide hydrolase (FAAH) | ||||||||||
| 6.80 | 52.0 | An adamantyl-substituted derivative of Δ8-THC, it is a potent and fairly selective CB1 full agonist and a moderately potent CB2 agonist. | |||||||||
| 32.1 | CB2 (165×) | 4.19 | A potent and selective inverse agonist for the cannabinoid receptor CB2 and a weak partial agonist at CB1. | ||||||||
| 1-(N-methyl-2-piperidine)methyl-2-methyl-3-(2-iodo)benzoylindole[5] | |||||||||||
| 9.00 ± 5.00 | 2.94 ± 2.65 | CB2 | 5.68 | Another name for JWH-018, it is a full agonist at both cannabinoid receptors with some selectivity for CB2. | |||||||
| 13.5 | 49.5 | 6.04 | An iodobenzoylindole which acts as a moderately potent agonist for both cannabinoid receptors. | ||||||||
| 0.08 | 1.44 | CB1 (18×) | 5.54 | An iodobenzoylindole which acts as a potent and selective agonist for the CB1 cannabinoid receptor. | |||||||
| 8.9 | 7.4 | 3-bornyl-Δ8-THC, a mixed CB1 / CB2 agonist.[6] | |||||||||
| 22.3 | 58.6 | CB1 | 7.1 | An analgesic derivative of Δ8-tetrahydrocannabinol, it is an agonist at both CB1 and CB2 with moderate selectivity for CB1. | |||||||
| 5.3 | 95 | A chlorine-substituted stereoisomer of anandamide. | |||||||||
| 9.9 | 226 | An allyl-substituted stereoisomer of anandamide. | |||||||||
| 1.2 | 5.3 | CB1 | 4.98 | A potent and reasonably selective agonist for the CB1 cannabinoid receptor. | |||||||
| 0.8 | 9.5 | CB1 | 4.98 | A potent and dodecally selective agonist for the CB1 cannabinoid receptor. | |||||||
| 2.2 | 3.4 | CB1 | 6.21 | A potent agonist at both CB1 and CB2 with moderate selectivity for CB1. It is a derivative of HU-210 and represents a hybrid structure between the classical and nonclassical cannabinoid families. | |||||||
| 2.2 | 4.3 | CB1 | A potent agonist at both CB1 and CB2 with moderate selectivity for CB1. It is a derivative of HU-210 and represents a hybrid structure between the classical and nonclassical cannabinoid families. | ||||||||
| 1.2 | 0.3 | CB2 (4×) | 5.92 | A potent agonist at both CB1 and CB2. It is a derivative of HU-210 and represents a hybrid structure between the classical and nonclassical cannabinoid families. | |||||||
| 7.4 | A dimethylated stereoisomer of anandamide. | ||||||||||
| An endocannabinoid analog specifically designed to be a potent and selective inhibitor of AEA uptake that is resistant to FAAH hydrolysis. | |||||||||||
| 3.88 | 73.4 | CB1 (19×) | 4.73 | A potent and selective analgesic CB1 agonist (as racemate). The (R) enantiomer has around 1000× higher affinity for CB1 than (S) enantiomer.[7] [8] | |||||||
| 52.3 | 0.28 | CB2 (187×) | A potent and selective CB2 agonist. | ||||||||
| 1.5 | 20.4 | CB1 (13×) | A moderately CB1 selective agonist. | ||||||||
| 3.4 | CB2 (80×) | A potent and selective analgesic CB2 agonist.[9] | |||||||||
| CB1 | A moderately potent agonist with some selectivity for CB1, containing an unusual 3-(adamant-1-oyl) substitution on the indole ring. | ||||||||||
| CB2 (54×) | A CB2 selective cannabilactone.[10] Acts as a dual CB2 agonist / CB1 antagonist.[11] | ||||||||||
| Cannabilactone | CB2 (490×) | 6.17 | A CB2 selective cannabilactone. | ||||||||
| A nonclassical cannabinoid[12] | |||||||||||
| 1.0 | 2.6 | CB1 | 5.18 | A potent agonist at both CB1 and CB2 with moderate selectivity for CB1. | |||||||
| 1.4 | 18.9 | CB1 | A potent agonist at both CB1 and CB2 with dodecal selectivity for CB1. | ||||||||
| 3.0 | 30 | CB1 (10×) | A potent agonist at both CB1 and CB2. | ||||||||
| 0.28 | 1.48 | 4.75 | A potent agonist at both CB1 and CB2. | ||||||||
| 1.8 | 2.2 | CB1 | 5.09 | The (R) enantiomer is potent and selective CB1 agonist used in 131I radiolabelled form to map distribution of CB1 receptors in brain.[13] [14] [15] [16] [17] [18] | |||||||
| 0.16 | CB1 (26×) | 6 | Classical cannabinoid derivative. | ||||||||
| 33000 | 26000 | An analog of oleoylethanolamide, the endogenous agonist for proliferator-activated receptor α (PPARα). It also acts as a weak cannabinoid agonist. | |||||||||
| 0.7 | 8.6 | CB1 (12×) | 6.17 | A potent agonist at both CB1 and CB2, it is dodecally selective for CB1. It is a derivative of HU-210 and represents a hybrid structure between the classical and nonclassical cannabinoid families. | |||||||
| 2.2 | CB1 (40×) | A potent but slow-onset agonist.[19] [20] | |||||||||
| 0.041 | 6.51 | Another name for HU-243, it is a potent agonist at both the CB1 and CB2 receptors. | |||||||||
| CB1 | A CB1 selective neutral antagonist.[21] | ||||||||||
| CB1 | 4.06 | A peripherally selective silent antagonist of CB1 receptors. | |||||||||
| A potent agonist of CB1 and CB2 with reduced duration of action.[22] | |||||||||||